Corporate Presentation

Indoco Remedies Ltd

Company ProfileA fast growing, fully integrated, research oriented pharmaceutical company

with a Global presence

Revenues in FY 2013-14 `7277 Mn (US $ 121 Mn)

Domestic business contributes 64% and international business contributes 36% of the revenues

Formulation business contributes 93% and API business contributes 7% of revenues

Workforce of over 4500

- 200 R&D scientists

- 2300 field staff

Our Infrastructure

Corporate Office at Santacruz (E), Mumbai

8 Manufacturing Facilities - 5 FDFs - 3 APIs

R&D Centre at Navi Mumbai

29 C&Fs

Mfg. Facilities for FDFs LOCATIO

NDOSAGE FORM APPROVALS

GOA ITABLETS, CREAMS

& OINTMENTS

US-FDA, EU-GMP, TGA Australia,

MCC South Africa,ANVISA - Brazil

GOA IISTERILE

PRODUCTS

US-FDA, EU-GMP, MCC South Africa,

TGA Australia

GOA III TABLETSUS-FDA, EU-GMP, TGA Australia,

WALUJ TABLETS Emerging Markets

BADDITABLETS, LIQUID

ORALS & TOOTHPASTES

EU–GMP and Emerging Markets

API facilities Multi-ton : Patalganga (USFDA , TGA Australia

approved)

- Reactor Capacity: 500 to 5000 L

Kilo Scale: Navi Mumbai (USFDA , TGA Australia approved)

- Reaction Systems: 16 to 500 L - Total Reactor Volume: 1 cubic meters - Temperatures range: -55 to + 150 celsius

Intermediates : Rabale

- Reactor Capacity: 500 to 3000 L - Total Reactor Volume: 50 cubic meters

Research & Development

US $ 10 Mn Investment in R&D set-up

Spread over an area of 150,000 square feet and employs over 200 scientists and technical personnel

58 Patents filed - 38 for APIs - 20 for FDFs

Business Model

• Branded Generics - 8 Marketing Divisions - 18 Therapeutic Segments - 150 Brands

• APIs

• Regulated Markets - Generic Business - CRAMS - Alliances

• Emerging Markets - Branded Generics - Through Distributors - Alliance

INTERNATIONAL BUSINESS

(Covers 80 countries)

INDIAN BUSINESS

Ranked 27th by CMARC in Rx Ranking Ranked 28th by AWACS in SSA Audit (Sept’14)

8 MARKETING DIVISIONS

INDOCO GPs, CPs, Gynaec, Pediatrician

SPADE GPs, CPs, Pediatrician, ENTs, Otologicals

WARREN Dental

EXCEL Opthalmic

SPERA GPs, Gynaec, Pediatrician

ETERNA CPs, Orthos, Gastro

INDOCO CND

Lifestyle / Cardio & Diabetology

INSTITUTION

Caters to Hospital & Government Supplies

Indian Business

Growth Drivers (Domestic Business)

Growing middle class population, increasing income levels, rapid urbanization, demand for quality healthcare services & changing lifestyle

Focus on chronic segment

Penetration in Northern and Eastern Regions

New Products introductions (around 20 products every year)

Growth above Industry Average

International Business

Revenue of

Rs. 2005 Mn in FY14

(US $ 33 Mn)

Revenue contribution

UK 48%, USA 23 %,

SA 12%, Germany 8%)

CRAMS,

Dossier Out-Licensing,

Out-Licensing of MAs

Actavis (Watson) Partnership

Regulated Markets

(85% of

Formulation

Export Business)

Revenue of

Rs. 307 Mn in FY14

(US $ 5 Mn)

Revenue contribution

Africa 8%, Asia 2%,

Latam 2%

Promotion of Branded

Generics through

Distributors

Aspen Partnership

Emerging Markets

(15% of

Formulation

Export Business)

Strong Partnership with Watson Pharmaceuticals Inc., USA

Multi-product, Multi-territory alliance with Aspen Pharmacare, SA

Own filing of ANDAs and Dossiers

NDDS and new technology platforms

Growth Drivers (International Business)

Segment wise Break-up and Contribution

68%

27%

5%

2008-09

61%

32%

6%

2013-14

91%

7% 2%

2003-04

(` In Lacs) Profit & Loss A/C – Percentage to Net Sales

Particulars

Quarter Ended Half Year Ended Year Ended

31.03.14

(Audited)

% to Sales 30.09.14

(Unaudited) % to Sales

30.09.13 (Unaudited)

% to Sales

30.09.14 (Unaudited)

% to Sales

30.09.13 (Unaudited)

% to Sales

INCOME                     Net Sales / Income from Operations 22642   19505   42437   34310  

71737   Add: Other Operating Income 201   726   269   1318   1034   Total Income from Operations 22843   20231   42706   35628   72771

  Add: Other Income 56   46   118   62   175   Total Income 22899   20277   42824   35690   72946                        EXPENDITURE                     Material Cost 7971 35.2 7576 38.8 15228 35.9 13545 39.5 26916 37.5

Employees Benefit Expenses 3596 15.9 3338 17.1 6970 16.4 6221 18.1 12905 18.0

Research & Development Expenses 489 2.2 384 2.0 918 2.2 658 1.9 1443 2.0

Other Expenses 5924 26.2 5635 28.9 11070 26.1 9468 27.6 19500 27.2

Finance Cost 268 1.2 527 2.7 541 1.3 1149 3.3 1880 2.6

Depreciation and Amortisation Expenses 1315 5.8 772 4.0 2262 5.3 1505 4.4 3091 4.3

Misc. Expenditure Written Off. - - - - -   - - 1 - Total Expenses 19563   18232   36989   32546   65735   PBT 3336 14.7 2045 10.5 5835 13.7 3144 9.2 7211 10.1

Tax Expenses 1095   441   1590   622   1421   PAT 2241 9.9 1604 8.2 4245 10.0 2522 7.4 5790 8.1

EBIDTA (w/o R&D) 5352 23.6 3682 18.9 9438 22.2 6394 18.6 13451 18.8

EBIDTA (with R&D) 4863 21.5 3298 16.9 8520 20.1 5736 16.7 12008 16.7

Operating Profit 3769 16.7 2383 12.2 6635 15.6 3740 10.9 8479 11.8